Scott-Edil Pharmacia Ltd, Baddi, Himachal Pradesh, and Skanttr Lifescience LLP, Ahmedabad, Gujarat have been given manufacturing and marketing licences for the commercial use of Prussian blue insoluble formulations created under the Technology Development Fund (TDF) scheme by the Drugs Controller General of India (DCGI). The firm created the medication based on technologies created by the Defence Research & Development Organization’s Institute of Nuclear Medicine & Allied Sciences (INMAS), a lab in Delhi (DRDO).
Pru-DecorpTM and PruDecorp-MG are the brand names for the medication. Cesium and Thallium decontamination is accomplished using the formulas. The World Health Organization (WHO) has designated it as one of the essential medications for radiological and nuclear crises.
Dr. Samir V. Kamat, Secretary of Defence R&D and Chairman of DRDO, has congratulated the Organization and the Industry on this accomplishment. He claimed that the DRDO’s efforts to promote the sector and realise Prime Minister Shri Narendra Modi’s vision of “Aatmanirbhar Bharat” were successful as evidenced by the development of these medication formulations under the TDF programme and the clearance of DCGI.
